Coya Therapeutics, Inc.
COYA·NasdaqCM
4.8100−0.1400 (−2.83%)today
At close: Oct 12, 4:00 PM EDT · May be delayed up to 15 min · USD
After hours4.8300+0.0200 (+0.42%)Oct 12, 4:00 PM EDT
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Previous close4.9500
Open5.0000
Day range4.81005.0500
52-week range3.71007.7500
Off day high−4.75%
Off 52-week high−37.94%
Volume100.72K
Avg. volume (3M)154.30K
Market cap112.83M
EPS (TTM)-1.07
Forward P/E-2.56
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)—
Shares outstanding23.46M
Short interest—
Earnings dateAug 11, 2026 (est.)
Analyst target—
Profit margin—
Against its peers
Compare in full ›| COYA | ACIU | VYGR | INMB | TVGN | CABA | |
|---|---|---|---|---|---|---|
| Market cap | 112.83M | 243.60M | 139.87M | 49.40M | 43.49M | 303.49M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -2.6 | 4.1 | -1.8 | -4.1 | — | -1.5 |
| Price/book | 2.6 | 5.8 | 0.9 | 2.4 | -1.5 | 1.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −18.32% | −20.20% | −49.90% | +3.28% | −81.03% | −22.49% |
| Today | −2.83% | −2.00% | −7.35% | −5.82% | −1.50% | −7.25% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All COYA news ›Coya Therapeutics Completes Enrollment of 120 Patients in COYA 302 ALS Trial
The Clinical Trial Vanguard Coya Therapeutics Completes Enrollment of 120 Patients in COYA 302 ALS Trial Coya Therapeutics closed enrollment in its Phase 2/3 ALSTARS trial on October 5, reaching its planned 120 patients for COYA 302, a…
Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
120th participant has been enrolled in ALSTARS trial achieving target enrollment Additional eligible participants already in active screening will be allowed to enroll Topline data from 24-week double-blind treatment phase on track for…
From articles in the 4Search news index.